Clinical trial · Observational
A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast
NCT03047889CI-TRIAL-00025885unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To study the epidemiological trends and characteristics for advanced breast cancer patients, to analyze these trends and report the results
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| standard therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Survival status at 3 years
- timeFrame
- 3 years
- description
- percentage of patients still alive at 3 years
Secondary outcomes (2)
- measure
- PFS
- timeFrame
- 3 years
- description
- Progression-free survival of first line therapy
- measure
- Survival status at 5 years
- timeFrame
- 3 years
- description
- percentage of patients still alive at 5 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * diagnosed as advanced breast cancer during Jan1st,2012-Dec31st,2014 * complete with surgical pathology data, auxiliary treatment, there is a clear recurrence, transfer time, place, transfer of recurrence after treatment, and curative effect evaluation details.In any age, ethnic group cases. Exclusion Criteria: * no available medical record
References
Publications (4)
- DERIVEDHan YQ, Yi ZB, Yu P, Wang WN, Ouyang QC, Yan M, Wang XJ, Hu XC, Jiang ZF, Huang T, Tong ZS, Wang SS, Yin YM, Li H, Yang RX, Yang HW, Teng YE, Sun T, Cai L, Li HY, Ouyang XN, He JJ, Liu XL, Yang SE, Qiao YL, Fan JH, Wang JY, Xu BH. Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China. J Oncol. 2021 Sep 15;2021:6621722. doi: 10.1155/2021/6621722. eCollection 2021. PMID 34567118
- DERIVEDGuo F, Yi Z, Wang W, Han Y, Yu P, Zhang S, Ouyang Q, Yan M, Wang X, Hu X, Jiang Z, Huang T, Tong Z, Wang S, Yin Y, Li H, Yang R, Yang H, Teng Y, Sun T, Cai L, Li H, Chen X, He J, Liu X, Yang S, Fan J, Qiao Y, Wang J, Xu B. Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nation-wide multicenter study. Cancer Med. 2021 Oct;10(19):6744-6761. doi: 10.1002/cam4.4215. Epub 2021 Sep 2. PMID 34472719
- DERIVEDWu Y, Han Y, Yu P, Ouyang Q, Yan M, Wang X, Hu X, Jiang Z, Huang T, Tong Z, Wang S, Yin Y, Li H, Yang R, Yang H, Teng Y, Sun T, Cai L, Li H, Chen X, He J, Liu X, Yang S, Qiao Y, Fan J, Wang J, Xu B. Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China. Front Oncol. 2021 Feb 11;10:599604. doi: 10.3389/fonc.2020.599604. eCollection 2020. PMID 33643905
- DERIVEDYi ZB, Yu P, Zhang S, Wang WN, Han YQ, Ouyang QC, Yan M, Wang XJ, Hu XC, Jiang ZF, Huang T, Tong ZS, Wang SS, Yin YM, Li H, Yang RX, Yang HW, Teng YE, Sun T, Cai L, Li HY, Chen X, He JJ, Liu XL, Yang SE, Wang JY, Fan JH, Qiao YL, Xu BH. Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological study. Int J Cancer. 2021 Feb 1;148(3):692-701. doi: 10.1002/ijc.33227. Epub 2020 Aug 19. PMID 32700765